JP2020073494A5 - - Google Patents

Download PDF

Info

Publication number: JP2020073494A5
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; aqueous pharmaceutical; composition according; pirfenidone; dose
Prior art date: 2019-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2019224873A

Other languages

English (en)

Japanese (ja)

Other versions

JP7120984B2 (ja

JP2020073494A (ja

Filing date

2019-12-12

Publication date

2020-11-26

2019-12-12 Application filed filed Critical

2020-05-14 Publication of JP2020073494A publication Critical patent/JP2020073494A/ja

2020-11-26 Publication of JP2020073494A5 publication Critical patent/JP2020073494A5/ja

2022-02-21 Priority to JP2022024945A priority Critical patent/JP2022078126A/ja

2022-08-17 Application granted granted Critical

2022-08-17 Publication of JP7120984B2 publication Critical patent/JP7120984B2/ja

2024-03-14 Priority to JP2024040308A priority patent/JP2024095678A/ja

Status Active legal-status Critical Current

2033-07-24 Anticipated expiration legal-status Critical

Links

239000008194 pharmaceutical composition Substances 0.000 claims 23
239000007788 liquid Substances 0.000 claims 11
230000008685 targeting Effects 0.000 claims 8
239000000443 aerosol Substances 0.000 claims 7
ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 7
229960003073 pirfenidone Drugs 0.000 claims 7
239000003446 ligand Substances 0.000 claims 6
239000006199 nebulizer Substances 0.000 claims 6
150000003384 small molecules Chemical class 0.000 claims 5
208000029523 Interstitial Lung disease Diseases 0.000 claims 3
239000007864 aqueous solution Substances 0.000 claims 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
210000004072 lung Anatomy 0.000 claims 3
150000003839 salts Chemical class 0.000 claims 3
102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
230000037396 body weight Effects 0.000 claims 2
229940079593 drug Drugs 0.000 claims 2
229940126864 fibroblast growth factor Drugs 0.000 claims 2
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims 2
239000006186 oral dosage form Substances 0.000 claims 2
230000003204 osmotic effect Effects 0.000 claims 2
239000002245 particle Substances 0.000 claims 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims 2
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 1
102100031168 CCN family member 2 Human genes 0.000 claims 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 1
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims 1
101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 claims 1
-1 IW001 Proteins 0.000 claims 1
108010005716 Interferon beta-1a Proteins 0.000 claims 1
102000008070 Interferon-gamma Human genes 0.000 claims 1
108010074328 Interferon-gamma Proteins 0.000 claims 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims 1
108010089484 PRM-151 Proteins 0.000 claims 1
102100036202 Serum amyloid P-component Human genes 0.000 claims 1
102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
239000003963 antioxidant agent Substances 0.000 claims 1
230000003078 antioxidant effect Effects 0.000 claims 1
210000004204 blood vessel Anatomy 0.000 claims 1
229910001622 calcium bromide Inorganic materials 0.000 claims 1
239000001110 calcium chloride Substances 0.000 claims 1
229910001628 calcium chloride Inorganic materials 0.000 claims 1
WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 claims 1
239000002738 chelating agent Substances 0.000 claims 1
239000006184 cosolvent Substances 0.000 claims 1
230000008021 deposition Effects 0.000 claims 1
235000003599 food sweetener Nutrition 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
229960004461 interferon beta-1a Drugs 0.000 claims 1
229960003130 interferon gamma Drugs 0.000 claims 1
150000002500 ions Chemical class 0.000 claims 1
OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 claims 1
229910001623 magnesium bromide Inorganic materials 0.000 claims 1
229910001629 magnesium chloride Inorganic materials 0.000 claims 1
239000012528 membrane Substances 0.000 claims 1
XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
229960004378 nintedanib Drugs 0.000 claims 1
239000008363 phosphate buffer Substances 0.000 claims 1
230000002685 pulmonary effect Effects 0.000 claims 1
239000011780 sodium chloride Substances 0.000 claims 1
239000007921 spray Substances 0.000 claims 1
239000004094 surface-active agent Substances 0.000 claims 1
239000003765 sweetening agent Substances 0.000 claims 1
239000006068 taste-masking agent Substances 0.000 claims 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
230000001256 tonic effect Effects 0.000 claims 1
239000000080 wetting agent Substances 0.000 claims 1

JP2019224873A 2012-07-24 2019-12-12 エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 Active JP7120984B2 (ja)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
JP2022024945A JP2022078126A (ja)	2012-07-24	2022-02-21	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2024040308A JP2024095678A (ja)	2012-07-24	2024-03-14	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US201261675286P	2012-07-24	2012-07-24
US61/675,286		2012-07-24
US201361756983P	2013-01-25	2013-01-25
US61/756,983		2013-01-25
US201361824818P	2013-05-17	2013-05-17
US61/824,818		2013-05-17

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018116525A Division JP2018172402A (ja)	2012-07-24	2018-06-19	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2022024945A Division JP2022078126A (ja)	2012-07-24	2022-02-21	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Publications (3)

Publication Number	Publication Date
JP2020073494A JP2020073494A (ja)	2020-05-14
JP2020073494A5 true JP2020073494A5 (2)	2020-11-26
JP7120984B2 JP7120984B2 (ja)	2022-08-17

Family

ID=49997965

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
JP2015524425A Active JP6501264B2 (ja)	2012-07-24	2013-07-24	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2018116525A Pending JP2018172402A (ja)	2012-07-24	2018-06-19	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2019224873A Active JP7120984B2 (ja)	2012-07-24	2019-12-12	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2022024945A Pending JP2022078126A (ja)	2012-07-24	2022-02-21	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2024040308A Pending JP2024095678A (ja)	2012-07-24	2024-03-14	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
JP2015524425A Active JP6501264B2 (ja)	2012-07-24	2013-07-24	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2018116525A Pending JP2018172402A (ja)	2012-07-24	2018-06-19	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2022024945A Pending JP2022078126A (ja)	2012-07-24	2022-02-21	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
JP2024040308A Pending JP2024095678A (ja)	2012-07-24	2024-03-14	エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Country Status (8)

Country	Link
EP (1)	EP2877164B1 (2)
JP (5)	JP6501264B2 (2)
AU (5)	AU2013295800A1 (2)
CA (1)	CA2880011C (2)
ES (1)	ES2959198T3 (2)
HU (1)	HUE063581T2 (2)
NZ (1)	NZ705260A (2)
WO (1)	WO2014018668A2 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10105356B2 (en)	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012106382A1 (en)	2011-01-31	2012-08-09	Genoa Pharmaceuticals, Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
EP3782604A1 (en)	2013-07-31	2021-02-24	Windward Pharma, Inc.	Aerosol tyrosine kinase inhibitor compounds and uses thereof
AU2015204558B2 (en)	2014-01-10	2020-04-30	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
CA3103604C (en) *	2016-03-28	2023-09-26	Presage Biosciences, Inc.	Pharmaceutical combinations for the treatment of cancer
US10238821B2 (en) *	2016-10-11	2019-03-26	Microdose Therapeutx, Inc.	Inhaler and methods of use thereof
WO2018234527A1 (en) *	2017-06-22	2018-12-27	Softhale Nv	Aerosol delivery of pirfenidone
CN117861026A (zh)	2017-06-22	2024-04-12	索芙特海尔公司	用于吡非尼酮气雾剂的吸入装置、储存器以及递送方法
GB201807050D0 (en) *	2018-04-30	2018-06-13	Cellprotect Nordic Pharmaceuticals Ab	Medical uses
WO2020219168A1 (en)	2019-04-24	2020-10-29	Convergene, Llc	Small molecule bromodomain inhibitors and uses thereof
EP3976570A1 (en) *	2019-05-27	2022-04-06	DSM IP Assets B.V.	Selective hydrogenation of alkynes to alkenes in the presence of a phosphorus compound and an organic sulphur compound
CN115666533B (zh) *	2020-04-22	2024-08-09	永进药品工业株式会社	具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法
IL303431A (en) *	2020-12-07	2023-08-01	Mannkind Corp	Method and composition for the treatment of pulmonary fibrosis
US12508228B2 (en)	2022-03-30	2025-12-30	The Chinese University Of Hong Kong	PFD loaded microspheres and method for preparing injectable composite microsphere hydrogel solution from same
CN115970069B (zh) *	2022-12-13	2024-09-24	南通大学附属医院	载吡非尼酮纳米粒子复合涂层输尿管支架管的制备方法
CN119548479A (zh) *	2024-12-31	2025-03-04	延边大学	一种吸入用吡非尼酮溶液及其使用方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3826255A (en)	1972-06-22	1974-07-30	Hudson Oxygen Therapy Sales Co	Intermittent positive pressure breathing manifold
YU41046B (en)	1974-08-22	1986-10-31	Schering Ag	Medicine inholating device
ZA757570B (en)	1974-12-09	1977-07-27	Affiliated Med Res	A useful n-substituted pyridone
US4268460A (en)	1977-12-12	1981-05-19	Warner-Lambert Company	Nebulizer
US4253468A (en)	1978-08-14	1981-03-03	Steven Lehmbeck	Nebulizer attachment
US4263907A (en)	1979-05-14	1981-04-28	Lindsey Joseph W	Respirator nebulizer
US4510929A (en)	1982-04-30	1985-04-16	Bordoni Maurice E	Disposable radioactive aerosol inhalation apparatus
US4649911A (en)	1983-09-08	1987-03-17	Baylor College Of Medicine	Small particle aerosol generator for treatment of respiratory disease including the lungs
US4624251A (en)	1984-09-13	1986-11-25	Riker Laboratories, Inc.	Apparatus for administering a nebulized substance
US5152456A (en)	1989-12-12	1992-10-06	Bespak, Plc	Dispensing apparatus having a perforate outlet member and a vibrating device
US5164740A (en)	1991-04-24	1992-11-17	Yehuda Ivri	High frequency printing mechanism
DK0540775T3 (da)	1991-11-07	1997-08-25	Ritzau Pari Werk Gmbh Paul	Forstøver især til anvendelse i apparater til inhalationsterapi
ATE131421T1 (de)	1991-12-04	1995-12-15	The Technology Partnership Plc	Vorrichtung und verfahren zur erzeugung von fluessigkeitstroepfchen
US5558085A (en)	1993-01-29	1996-09-24	Aradigm Corporation	Intrapulmonary delivery of peptide drugs
US5934272A (en)	1993-01-29	1999-08-10	Aradigm Corporation	Device and method of creating aerosolized mist of respiratory drug
US5709202A (en)	1993-05-21	1998-01-20	Aradigm Corporation	Intrapulmonary delivery of aerosolized formulations
JP4484247B2 (ja)	1995-02-24	2010-06-16	エランファーマインターナショナル，リミティド	ナノ粒子分散体を含有するエアロゾル
US5758637A (en)	1995-08-31	1998-06-02	Aerogen, Inc.	Liquid dispensing apparatus and methods
US5586550A (en)	1995-08-31	1996-12-24	Fluid Propulsion Technologies, Inc.	Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US6427682B1 (en)	1995-04-05	2002-08-06	Aerogen, Inc.	Methods and apparatus for aerosolizing a substance
US5823179A (en)	1996-02-13	1998-10-20	1263152 Ontario Inc.	Nebulizer apparatus and method
US6083922A (en)	1996-04-02	2000-07-04	Pathogenesis, Corp.	Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5906202A (en)	1996-11-21	1999-05-25	Aradigm Corporation	Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6349719B2 (en)	1997-02-24	2002-02-26	Aradigm Corporation	Formulation and devices for monitoring the efficacy of the delivery of aerosols
DE19713636A1 (de)	1997-04-02	1998-10-08	Pari Gmbh	Atemzugsimulator
US5855564A (en)	1997-08-20	1999-01-05	Aradigm Corporation	Aerosol extrusion mechanism
ES2175799T3 (es)	1997-10-08	2002-11-16	Sepracor Inc	Forma de dosificacion para administracion en aerosol.
DK0923957T3 (da)	1997-11-19	2002-02-18	Microflow Eng Sa	Dyseemne og væskedråbesprøjteindretning til en inhalator egnet til respirationsterapi
US6192876B1 (en)	1997-12-12	2001-02-27	Astra Aktiebolag	Inhalation apparatus and method
JP2002526447A (ja)	1998-09-18	2002-08-20	メファ・アクチェンゲゼルシャフト	アルキルフェニルピリドンの局所製剤
GB2343122B (en)	1998-10-26	2003-01-08	Medic Aid Ltd	Improvements in and relating to nebulisers
US6070575A (en)	1998-11-16	2000-06-06	Aradigm Corporation	Aerosol-forming porous membrane with certain pore structure
US6584971B1 (en)	1999-01-04	2003-07-01	Medic-Aid Limited	Drug delivery apparatus
US6338443B1 (en)	1999-06-18	2002-01-15	Mercury Enterprises, Inc.	High efficiency medical nebulizer
US6962151B1 (en)	1999-11-05	2005-11-08	Pari GmbH Spezialisten für effektive Inhalation	Inhalation nebulizer
EP1272243B1 (en)	2000-04-11	2005-10-26	Trudell Medical International	Aerosol delivery apparatus with positive expiratory pressure capacity
US6601581B1 (en)	2000-11-01	2003-08-05	Advanced Medical Applications, Inc.	Method and device for ultrasound drug delivery
DE10102846B4 (de)	2001-01-23	2012-04-12	Pari Pharma Gmbh	Aerosolgenerator
EP1304131B1 (de)	2001-10-18	2005-06-29	PARI GmbH Spezialisten für effektive Inhalation	Inhalationstherapievorrichtung
ATE269735T1 (de)	2001-10-18	2004-07-15	Pari Gmbh	Inhalationstherapievorrichtung
WO2003035030A1 (en)	2001-10-24	2003-05-01	Pari Gmbh	Kit for the preparation of a pharmaceutical composition
US7550133B2 (en) *	2002-11-26	2009-06-23	Alexza Pharmaceuticals, Inc.	Respiratory drug condensation aerosols and methods of making and using them
JP4542743B2 (ja) *	2002-12-26	2010-09-15	Ｋｄｌ株式会社	ピリドン誘導体の溶液状医薬組成物
US7838532B2 (en)	2005-05-18	2010-11-23	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
JP2010533181A (ja) *	2007-07-13	2010-10-21	アボツト・バイオテクノロジー・リミテツド	ＴＮＦα阻害剤の肺投与のための方法及び組成物
EP2237788A4 (en) *	2007-12-27	2013-06-05	Aires Pharmaceuticals Inc	COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
KR101959873B1 (ko) *	2008-10-07	2019-03-19	랩터 파마슈티컬스 인코포레이티드	약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
AU2010302420B2 (en) *	2009-10-02	2013-07-04	Astrazeneca Ab	2-pyridone compounds used as inhibitors of neutrophil elastase
JP6239054B2 (ja) *	2010-11-26	2017-11-29	東芝メディカルシステムズ株式会社	磁気共鳴診断装置
WO2012106382A1 (en) *	2011-01-31	2012-08-09	Genoa Pharmaceuticals, Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof

2013
- 2013-07-24 EP EP13822166.8A patent/EP2877164B1/en active Active
- 2013-07-24 NZ NZ705260A patent/NZ705260A/en unknown
- 2013-07-24 HU HUE13822166A patent/HUE063581T2/hu unknown
- 2013-07-24 ES ES13822166T patent/ES2959198T3/es active Active
- 2013-07-24 CA CA2880011A patent/CA2880011C/en active Active
- 2013-07-24 AU AU2013295800A patent/AU2013295800A1/en not_active Abandoned
- 2013-07-24 WO PCT/US2013/051880 patent/WO2014018668A2/en not_active Ceased
- 2013-07-24 JP JP2015524425A patent/JP6501264B2/ja active Active
2018
- 2018-06-19 JP JP2018116525A patent/JP2018172402A/ja active Pending
- 2018-07-23 AU AU2018206852A patent/AU2018206852A1/en not_active Abandoned
2019
- 2019-12-12 JP JP2019224873A patent/JP7120984B2/ja active Active
2020
- 2020-03-03 AU AU2020201557A patent/AU2020201557B2/en active Active
2022
- 2022-02-21 JP JP2022024945A patent/JP2022078126A/ja active Pending
- 2022-11-16 AU AU2022271417A patent/AU2022271417A1/en not_active Abandoned
2024
- 2024-03-14 JP JP2024040308A patent/JP2024095678A/ja active Pending
- 2024-11-29 AU AU2024267029A patent/AU2024267029A1/en active Pending

Publication	Publication Date	Title
JP2020073494A5 (2)	2020-11-26
JP2024095678A5 (2)	2025-01-31
JP2018199688A5 (2)	2019-02-21
JP2015523395A5 (2)	2016-09-08
JP2019031514A5 (2)	2019-04-11
JP2017502064A5 (2)	2018-03-01
NZ760541A (en)	2022-08-26	Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP2014503598A5 (2)	2015-03-26
JP2017505348A (ja)	2017-02-16	肺疾患治療のための肥満細胞安定剤
JP2023542629A (ja)	2023-10-11	改良されたエアロゾルパラメータのための噴霧器デバイスの最適化及びその使用
CN103619323B (zh)	2016-08-17	作为气溶胶团的伊洛前列素的给药
EA022840B1 (ru)	2016-03-31	Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа
US20230158259A1 (en)	2023-05-25	Products of manufacture and methods for treating, ameliorating or preventing microbial infections
HRP20221185T1 (hr)	2022-12-09	Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom
CN104853744B (zh)	2018-01-19	气溶胶化伊洛前列素的给药
Hsu et al.	2005	Iloprost inhalation solution for the treatment of pulmonary arterial hypertension
US20180325908A1 (en)	2018-11-15	Methods and compositions for treating pulmonary hypertension
Standaert et al.	2000	The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer
MX2013004030A (es)	2013-06-05	Composicion farmaceutica a base de denufosol para tratar fibrosis quistica.
AU2020103517A4 (en)	2021-01-28	Ibp- nebulizer: intelligent nebulizer for bronchitis patients
CZ2007598A3 (cs)	2007-10-17	Prostredek pro rozprašovace
WO2010009288A1 (en)	2010-01-21	Compositions and uses of antiviral active pharmaceutical agents
KR20230035518A (ko)	2023-03-14	선천적 면역 반응을 생성하기 위한 퀴닌과 그의 용도
CN107137502A (zh)	2017-09-08	一种鱼腥草雾化吸入用溶液制剂及其制备方法
US20250352530A1 (en)	2025-11-20	Method and composition for treating lung diseases